Compare Expedia Group Inc (EXPE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Moderna, Inc. — how do they compare? Expedia Group Inc trades at $271.42 (market cap $32.42B), while Moderna, Inc. trades at $219.2 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 2.4× Expedia Group Inc's market cap, and Expedia Group Inc pays a 0.71% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and Moderna, Inc. for 59 Days on average.
| EXPE | MRNA | |
|---|---|---|
Market Cap | $32.42B | $78.65B |
Volume | 1,940,671 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $203.46 |
52-Week Low | $188.51 | $22.36 |
Typical Hold Time | 48 Days | 59 Days |
Enterprise Value | $30.98B | $74.80B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $271.44, up 4.86% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical signal, trading near resistance at $275, with solid fundamentals including a P/E of 16.99 and robust revenue growth to $14.73B in 2025. Recent news highlights competitive threats from AI agents but also underscores Expedia's strategic partnerships and B2B booking strength.
The outlook remains positive with a consensus price target of $335.06, implying 23% upside, supported by earnings momentum and market share gains. Key risks include AI disruption in travel booking and competitive pressures. Institutional sentiment is mixed but leans bullish, with growth in operating cash flow to $3.9B in 2025 providing a solid foundation.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
